Morgan Stanley Expands Global Inclusive Ventures Lab with Largest Single Cohort of 23 Companies
Morgan Stanley (NYSE: MS) today announced the 2023 global cohort of the Inclusive Ventures Lab, with 23 companies selected across North America and Europe, the Middle East and Africa (EMEA), double the size of previous cohorts. The Lab offers a five-month in-house accelerator program for underrepresented founders of technology and technology-enabled startups in the post-seed to Series A funding round stage.
Chosen from over 7,900 applicants – more than three times last year’s pool – the selected startups represent a range of disruptive technologies in industries including healthcare, sustainable solutions, customer service, supply chain, recruiting and cybersecurity. Companies in the cohort receive a $250,000 investment (£250,000 in EMEA) from Morgan Stanley, as well as a variety of mentorship opportunities and business-growth resources from Morgan Stanley’s ecosystem of internal and external partners.
“We are proud to welcome the Lab’s largest cohort yet, marking our continued efforts to create a more equitable investment landscape for overlooked entrepreneurs worldwide,” said Selma Bueno, Global Head of the Morgan Stanley Inclusive Ventures Group. “We are working to bridge the investment gap for underserved founders and to help correct documented market imbalances.”
The selected companies in the 2023 global cohort include the following:
- Ad Auris empowers marketing teams, publishers and content creators to repurpose written content into high-quality audio to reach an audience of listeners (Canada)
- Automated Architecture provides the technological infrastructure for a distributed robotic micro-factory network producing sustainable timber housing (UK)
- Bidrento offers an all-in-one solution for tenant experience and rental property management, helping to save time and money while also reducing CO2 emissions in real estate (Estonia)
- ByFusion provides a zero waste landfill diversion platform to transform non-recyclable plastic waste into reusable building materials (US)
- Cult Mia is an online fashion marketplace for sustainable and ethical brands from around the world (UK)
- DotLab develops breakthrough, actionable AI and ML technologies that lead to better health outcomes for women, starting with the diagnosis of endometriosis (US)
- eBanqo offers businesses an omnichannel platform to drive customer engagement and support (Nigeria)
- Encounter AI uses digital conversational ordering solutions to provide faster, friendlier and more efficient service to customers, restaurants and retailers (US)
- FLUIX Inc. enterprise AI software saves critical infrastructure on energy costs by integrating and optimizing facility systems (US)
- GigBridge is an online platform for construction companies to hire, onboard and pay their workforce all in one place (UK)
- Health in Her HUE connects Black women and women of color to culturally sensitive healthcare providers, health content and community support through a digital platform (US)
- Inicio AI delivers a virtually guided affordability assessment to help organizations save contact center costs while improving their end customer experience (UK)
- MEDIjobs is the first virtual recruiter for the healthcare industry, filling more than 55 types of positions at a rate five times faster than a human would (US)
- Nopalera is a collection of bath and body products powered by Mexico’s nopal cactus – an ancient symbol of Mexican culture (US)
- OKO offers affordable and inclusive crop insurance to farmers in emerging countries using satellite weather data and mobile payment technologies (Israel)
- Oppos provides robust cybersecurity and compliance security solutions for businesses, safeguarding data confidentiality, integrity, and availability (Canada)
- Partsimony enables organizations to build intelligent manufacturing supply chains that are more resilient and sustainable by unifying engineering and supply chain data (US)
- Ridelink leverages technology to enable small and medium-sized businesses to move cargo in Uganda and cross-border in six neighboring countries (Uganda)
- serviceMob is an AI & ML-powered customer service analytics platform that helps businesses optimize operations and improve the customer experience (US)
- Stak Mobility facilitates widespread urban electric vehicle adoption by merging space-saving vertical parking automation with fully integrated EV charging and a seamless mobile self-service experience (US)
- Tall Poppy is a digital security company protecting employees and public facing teams from online threats (US)
- Twipes uses bio-tech to produce flushable, biodegradable wet wipes that break down in water in three hours and biodegrade in landfills in seven days (US)
- Unfabled is a consumer health platform that delivers personalized solutions for women by matching them with health and wellness products (UK)
“We are thrilled to bring our unique accelerator program to more entrepreneurs globally, including our first participants from Africa and the Middle East,” said Sanghamitra Karra, EMEA Head of the Inclusive Ventures Group. “It is highly rewarding to work closely with founders to take their game-changing technologies to scale and help set them up for continued success.”
“By providing these promising startups with much-needed capital, a tailored curriculum and access to investors within and beyond the Firm’s far-reaching network, we aim to ensure that more underrepresented founders can succeed,” said LaToya Wilson, Americas Head of the Inclusive Ventures Group.
Programming will run through February 2024 and culminate in a global Demo Day, when participating companies will present to potential investors, business partners and customers.
The Inclusive Ventures Lab has won multiple Gold Anthem Awards, including Most Impactful Corporate Initiative in 2022 and Corporate Social Responsibility in 2023. The program was also listed as one of Global Finance’s Best Innovation Labs of 2023.
About the Morgan Stanley Inclusive Ventures Lab
The Morgan Stanley Inclusive Ventures Lab (MSIVL) is an intensive five-month in-house accelerator program designed to help further develop and scale startups, culminating in a showcase presentation and Demo Day to the investor community. Morgan Stanley launched MSIVL, formerly called the Multicultural Innovation Lab, in 2017 in order to address inequities in funding of underrepresented founders, which our research shows equals over four trillion dollars in unrealized returns.
About Morgan Stanley
Morgan Stanley (NYSE: MS) is a leading global financial services firm providing a wide range of investment banking, securities, wealth management and investment management services. With offices in 42 countries, the Firm’s employees serve clients worldwide including corporations, governments, institutions and individuals. For further information about Morgan Stanley, please visit www.morganstanley.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230911548537/en/
Contact information
Media Relations: Carrie Hall, carrie.hall@morganstanley.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom